Nerandomilast met the primary endpoint in the FIBRONEER-IPF trial, demonstrating a statistically significant absolute change from baseline in Forced Vital Capacity (FVC) at week 52 compared to placebo.
Nerandomilast (BI 1015550) is a potent and selective phosphodiesterase 4B (PDE4B) inhibitor demonstrating potential for treating idiopathic pulmonary fibrosis (IPF).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.